Currently approved and emerging oral therapies in multiple sclerosis: An update for the ophthalmologist.

Published

Journal Article (Review)

Although our understanding of multiple sclerosis (MS) has grown substantially, its cause remains unknown. Nonetheless, in the past 3 decades, there have been tremendous advancements in the development of disease-modifying drugs (DMDs). In July 1993, the United States Food and Drug Administration approved the first disease-modifying drug-interferon β- and there are currently 13 medications approved for use in relapsing MS. All the early medications are administered either as a subcutaneous or intramuscular injection, and despite the clinical efficacy and safety of these medications, many patients were hampered by the inconvenience of injections and injection-related side effects. In September 2010, the first oral DMD-fingolimod-was approved. Since then, 2 additional oral DMDs (teriflunomide and dimethyl fumarate) have been approved, and several other oral medications are being evaluated in extensive MS development programs. Because of frequent ocular involvement, ophthalmologists are often involved in the care of MS patients and therefore need to be aware of the current treatment regimens prescribed by neurologists, some of which can have significant ophthalmic adverse events. We update the current advancements in the treatment of MS and discuss the published clinical data on the efficacy and safety of the currently approved and emerging oral therapies in MS.

Full Text

Duke Authors

Cited Authors

  • Eckstein, C; Bhatti, MT

Published Date

  • May 2016

Published In

Volume / Issue

  • 61 / 3

Start / End Page

  • 318 - 332

PubMed ID

  • 26703886

Pubmed Central ID

  • 26703886

Electronic International Standard Serial Number (EISSN)

  • 1879-3304

Digital Object Identifier (DOI)

  • 10.1016/j.survophthal.2015.12.001

Language

  • eng

Conference Location

  • United States